All stock lists
Genmab A/S (NASDAQ:GMAB)
DK · Delayed Price · Currency is USD
Healthcare · Biotechnology
57.29+12.62 (+28.25%)
Market cap
$35.2B
Insider Score
Health Score
Analyst consensus
Listed since
Jun 1, 2009
Website
Insider Score
––Not scored
GMAB Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Strong
From GMAB’s reported statements · Q2 2026 (trailing 12 months)
Profitability20 / 20
Keeps a healthy share of every dollar it sells.
- Revenue
- $4.13B
- Net income
- $788.1M
- Net margin
- 19.1%
Leverage5 / 20
Heavily indebted for what it earns.
- Total debt
- $5.27B
- Cash
- $1.50B
- Net debt / EBITDA
- 3.09x
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $2.80B
- Current liabilities
- $1.14B
- Current ratio
- 2.46
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $890.3M
- Free cash flow
- $867.3M
- FCF margin
- 21.0%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 613.4M
- Share growth (1y)
- -0.7%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
GMAB Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 1.16 B | 899.32 M | 1.05 B | 1.02 B | 924.81 M | 105.23 M |
| Revenue Growth (YoY) | 24.89 % | 754.59 % | -83.62 % | -81.55 % | 18.72 % | -82.55 % |
| Cost of Revenue | 84.00 M | 65.24 M | 80.76 M | 58.00 M | 56.99 M | 6.18 M |
| Gross Profit | 1.07 B | 834.08 M | 974.05 M | 964.00 M | 867.82 M | 99.05 M |
| SG&A Expense | 205.00 M | 166.61 M | 207.37 M | 148.00 M | 143.97 M | 18.54 M |
| R&D Expense | 459.00 M | 441.63 M | 524.41 M | 357.00 M | 363.92 M | 52.84 M |
| Operating Expenses | 664.00 M | 608.24 M | 731.79 M | 505.00 M | 507.89 M | 71.38 M |
| Operating Income | 407.00 M | 225.83 M | 242.27 M | 459.00 M | 359.92 M | 27.67 M |
| Pretax Income | 295.00 M | 74.27 M | 54.83 M | 482.00 M | 422.91 M | 35.91 M |
| Tax Provision | -8.00 M | 21.08 M | 23.93 M | 81.00 M | 86.98 M | 7.21 M |
| Net Income | 303.00 M | 53.20 M | 30.91 M | 401.00 M | 335.93 M | 28.70 M |
| EPS (Basic) | 0.49 | 0.09 | 0.05 | 0.65 | 0.54 | 0.04 |
| EPS (Diluted) | 0.49 | 0.08 | 0.05 | 0.65 | 0.54 | 0.04 |
| Shares Outstanding | 613.36 M | 613.84 M | 616.19 M | 615.98 M | 617.65 M | 637.25 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.